Toxic posterior segment syndrome after dropless cataract surgery with compounded triamcinolone-moxifloxacin

Conclusion: This is the first case series of toxic posterior segment syndrome occurring secondary to intracameral compounded triamcinolone-moxifloxacin in dropless cataract surgery. The FDA has attributed the toxicity to abnormally high levels of the binding agent poloxamer 407 in the compounded medication. Clinicians should be aware of this phenomenon and exhibit caution when using compounded medications.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research